公开(公告)号：EP2416761B1

公开(公告)日：2015-02-11

申请号：EP10720884.5

申请日：2010-05-10

申请人： ratiopharm GmbH

发明人： FISCHER, Dirk ,  KOELLNER, Gertraud ,  AUER, Gertrud ,  RIMKUS, Katrin ,  MUSKULUS, Frank ,  BRUECK, Sandra ,  PAETZ, Jana

IPC分类号： A61K9/14 ,  A61K31/137 ,  A61P31/10 ,  A61K9/26 ,  A61K9/50 ,  C07C215/54 ,  C07C59/255

CPC分类号： C07C215/54 ,  A61K9/2081 ,  A61K9/2866 ,  A61K9/5047 ,  A61K31/137 ,  C07B2200/07 ,  C07C59/255

公开(公告)号：EP2603503B1

公开(公告)日：2015-08-05

申请号：EP11764455.9

申请日：2011-09-27

申请人： ratiopharm GmbH

发明人： FISCHER, Dirk

IPC分类号： C07D403/12 ,  A61K31/4439 ,  A61P9/00

CPC分类号： C07D401/12

公开(公告)号：EP2558440B1

公开(公告)日：2016-11-16

申请号：EP11714311.5

申请日：2011-04-14

申请人： ratiopharm GmbH

发明人： FISCHER, Dirk ,  MATZDORF, Thorsten ,  NESS, Winfried

IPC分类号： C07C231/24 ,  C07C233/18 ,  A61K31/165 ,  A61P25/24 ,  A61P3/10

CPC分类号： C07C233/18 ,  C07C231/24

公开(公告)号：EP2643314A1

公开(公告)日：2013-10-02

申请号：EP11794304.3

申请日：2011-11-23

申请人： Ratiopharm GmbH

发明人： GIDWANI, Ramesh, Matioram ,  HIREMATH, Channaveerayya ,  YADAV, Manoj, Dalsingar ,  ALBRECHT, Wolfgang ,  FISCHER, Dirk

IPC分类号： C07D405/12 ,  A61K31/517 ,  A61P35/00

CPC分类号： C07D405/12

摘要： Afatinib salts and crystalline forms thereof are described in the present application and processes for their preparation. Crystalline forms of Afatinib are also described in the present application and processes for their preparation. The present invention also includes pharmaceutical compositions of such Afatinib salts and crystalline forms thereof or crystalline forms of Afatinib, methods of their preparation and the use thereof in the treatment of a patient in need thereof.

公开(公告)号：EP2643314B1

公开(公告)日：2016-07-13

申请号：EP11794304.3

申请日：2011-11-23

申请人： ratiopharm GmbH

发明人： GIDWANI, Ramesh, Matioram ,  HIREMATH, Channaveerayya ,  YADAV, Manoj, Dalsingar ,  ALBRECHT, Wolfgang ,  FISCHER, Dirk

IPC分类号： C07D405/12 ,  A61K31/517 ,  A61P35/00

CPC分类号： C07D405/12

公开(公告)号：EP2416761A1

公开(公告)日：2012-02-15

申请号：EP10720884.5

申请日：2010-05-10

申请人： Ratiopharm GmbH

发明人： FISCHER, Dirk ,  KOELLNER, Gertraud ,  AUER, Gertrud ,  RIMKUS, Katrin ,  MUSKULUS, Frank ,  BRUECK, Sandra ,  PAETZ, Jana

IPC分类号： A61K9/14 ,  A61K31/137 ,  A61P31/10

CPC分类号： C07C215/54 ,  A61K9/2081 ,  A61K9/2866 ,  A61K9/5047 ,  A61K31/137 ,  C07B2200/07 ,  C07C59/255

摘要： The invention relates to desfesoterodine in the form of a tartaric acid salt, in particular in the polymorphic "form R", and to a process for the production thereof. In a second aspect, the invention relates to the desfesoterodine according to the invention in micro-encapsulated form.

公开(公告)号：EP2603503A1

公开(公告)日：2013-06-19

申请号：EP11764455.9

申请日：2011-09-27

申请人： ratiopharm GmbH

发明人： FISCHER, Dirk

IPC分类号： C07D403/12 ,  A61K31/4439 ,  A61P9/00

CPC分类号： C07D401/12

摘要： Dabigatran etexilate bismesylate and crystalline forms thereof are described in the present application and processes for their preparation. The present invention also includes pharmaceutical compositions of such Dabigatran etexilate bismesylate and crystalline forms thereof, methods of their preparation and the use thereof in the treatment of a patient in need thereof.

公开(公告)号：EP2558440A1

公开(公告)日：2013-02-20

申请号：EP11714311.5

申请日：2011-04-14

申请人： Ratiopharm GmbH

发明人： FISCHER, Dirk ,  MATZDORF, Thorsten ,  NESS, Winfried

IPC分类号： C07C231/24 ,  C07C233/18 ,  A61K31/165 ,  A61P25/24 ,  A61P3/10

CPC分类号： C07C233/18 ,  C07C231/24

摘要： The invention provides a process for the preparation of the polymorph from I of agomelatine, characterized by the following crystal data: C
15 H
17 N0
2 Mr = 243.30 Orthorhombic Pca2
1 a = 31.501 (4) Å b = 9.5280 (10) Å c = 17.906 (2) Å Z = 16 the process comprising the process steps of: a) dissolving agomelatine in a solvent to obtain a solution, b) adding the solution to an organic anti-solvent having a temperature of 30°C or below, whereby crystals of the polymorph form I of agomelatine are formed, wherein the solvent of step a) is miscible with the anti-solvent of step b), c) isolating the crystals of the polymorph form I of agomelatine and d) optionally drying the isolated crystals of the polymorph form I of agomelatine.